Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following positive advice from the Scottish Medicines Consortium (SMC), the first biologic treatment for inflammatory skin disease, hidradenitis suppurativa (HS), is now available in Scotland on the NHS.
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.
GSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59 who are at an increased risk for respiratory syncytial virus (RSV) infection.
A collaboration to expand autologous CAR-T programs into trials for multiple cancers in a cost-efficient way, has been formed by BioNTech SE and Autolus Therapeutics plc.